摘要
目的：分析恩替卡韦对失代偿期乙肝后肝硬化患者血清血栓调节蛋白水平以及胰岛素抵抗的影响。方法选择2013年1月-2014年2月我院收治的乙肝后肝硬化失代偿患者63例。观察组32例抗病毒治疗采用恩替卡韦，而对照组31例抗病毒治疗采用拉米夫定。结果治疗1年后，观察组3例死亡。对照组4例死亡。观察组血栓调节蛋白、血清胰岛素及胰岛素抵抗指数均低于对照组（t分别为4.049、3.252、5.850， P＜0.05）。结论恩替卡韦可缓解失代偿期乙肝后肝硬化患者血管内皮细胞损伤和胰岛素抵抗。
ObjectiveTo analyze entecavir of decompensated hepatitis B serum thrombosis in patients with liver cirrhosis regulating protein levels and insulin resistance.Methods Selecting 63 cases with hepatitis B liver cirrhosis in our hospital from January 2013 to February 2014. The observation group of 32 cases of antiviral therapy with entecavir,and 31 cases in the control group of antiviral therapy with lamivudine.Results After 1 years of treatment,3 patients in the observation group of death. Control group of 4 cases of death. The observation group,serum insulin and insulin resistance index were lower than the control group （t=4.049,3.252,5.850,P〈0.05）.Conclusion Entecavir can significantly relieve decompensated hepatitis B after injury of vascular endothelial cels and insulin resistance in patients with liver cirrhosis.
出处
《中国卫生标准管理》
2016年第17期86-88,共3页
China Health Standard Management
关键词
恩替卡韦
乙肝后肝硬化
血栓调节蛋白
胰岛素抵抗
Entecavir
Liver cirrhosis after hepatitis B
Thrombomodulin
Insulin resistance
